2seventy bio (NASDAQ:TSVT) Receives “Sell (D-)” Rating from Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of 2seventy bio (NASDAQ:TSVT) in a research report sent to investors on Friday morning,Weiss Ratings reports.

2seventy bio Price Performance

NASDAQ:TSVT opened at $2.66 on Friday. 2seventy bio has a 1 year low of $2.29 and a 1 year high of $5.99. The company has a market cap of $137.22 million, a P/E ratio of -1.43 and a beta of 1.73. The stock’s fifty day moving average price is $2.61 and its two-hundred day moving average price is $3.72.

Institutional Investors Weigh In On 2seventy bio

A number of institutional investors and hedge funds have recently made changes to their positions in TSVT. Erste Asset Management GmbH purchased a new stake in shares of 2seventy bio in the third quarter worth $25,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of 2seventy bio in the fourth quarter worth $32,000. BNP Paribas Financial Markets purchased a new stake in shares of 2seventy bio in the fourth quarter worth $35,000. ProShare Advisors LLC purchased a new stake in shares of 2seventy bio in the fourth quarter worth $48,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of 2seventy bio in the fourth quarter worth $52,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.